PI3K/mTORC1 Activation in Hamartoma Syndromes: Therapeutic Prospects

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2009 Jan 30

PMID 19177005

Citations 46

Authors

Vera P Krymskaya

Elena A Goncharova

Affiliations

Soon will be listed here.

Abstract

Dysregulated activity of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin complex 1 (mTORC1) is characteristic feature of hamartoma syndromes. Hamartoma syndromes, dominantly inherited cancer predisposition disorders, affect multiple organs and are manifested by benign tumors consisting of various cell types native to the tissues in which they arise. In the past few years, three inherited hamartoma syndromes, Cowden syndrome (CS), tuberous sclerosis complex (TSC) syndrome, and Peutz-Jeghens syndrome (PJS), have all been linked to a common biochemical pathway: the hyperactivation of PI3K/mTORC1 intracellular signaling. Three tumor suppressors, PTEN (phosphatases and tensin homolog), tuberous sclerosis complex TSC1/TSC2, and LKB1, are negative regulators of PI3K/mTORC1 signaling; disease-related inactivation of these tumor suppressors results in the development of PTEN-associated hamartoma syndromes, TSC and PJS, respectively. The goal of this review is to provide a roadmap for navigating the inherently complex regulation of PI3K/mTORC1 signaling while highlighting the progress that has been made in elucidating the cellular and molecular mechanisms of hamartoma syndromes and identificating potential therapeutic targets for their treatment. Importantly, because the PI3K/mTORC1 pathway is activated in the majority of common human cancers, the identification of novel molecular target(s) for the treatment of hamartoma syndromes may have a broader translational potential, and is critically important not only for therapeutic intervention in hamartoma disorders, but also for the treatment of cancers.

Citing Articles

Class III Phosphatidylinositol-3 Kinase/Vacuolar Protein Sorting 34 in Cardiovascular Health and Disease.

Shen Y, Gleghorn J J Cardiovasc Transl Res. 2025; .

PMID: 39821606 DOI: 10.1007/s12265-024-10581-z.

A New Variant of the PTEN Gene in Relation to Cowden Syndrome Type 1.

Fernandez-Villares M, Villegas-Romero I, Collantes-Rodriguez C, Linares-Barrios M, Benito-Godino A, Mora-Lopez F Indian J Dermatol. 2024; 69(3):274-276.

PMID: 39119301 PMC: 11305488. DOI: 10.4103/ijd.ijd_633_22.

Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension.

Shen Y, Goncharov D, Pena A, Baust J, Chavez Barragan A, Ray A Sci Signal. 2022; 15(763):eabn2743.

PMID: 36473049 PMC: 9869933. DOI: 10.1126/scisignal.abn2743.

CagA increases DNA methylation and decreases PTEN expression in human gastric cancer.

Zhang B, Zhang X, Jin M, Hu L, Zang M, Qiu W Mol Med Rep. 2018; 19(1):309-319.

PMID: 30431097 PMC: 6297774. DOI: 10.3892/mmr.2018.9654.

Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment.

McCann H, Johnson C, Errington R, Davies D, Dunlop E, Tee A Cancers (Basel). 2018; 10(10).

PMID: 30308940 PMC: 6210998. DOI: 10.3390/cancers10100375.

References

Wang L, Harris T, Lawrence Jr J . Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem. 2008; 283(23):15619-27. PMC: 2414301. DOI: 10.1074/jbc.M800723200. View

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

Waite K, Eng C . From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet. 2003; 4(10):763-73. DOI: 10.1038/nrg1178. View

WALKER E, Pacold M, Perisic O, Stephens L, Hawkins P, Wymann M . Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000; 6(4):909-19. DOI: 10.1016/s1097-2765(05)00089-4. View

Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R . Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007; 25(17):2406-13. DOI: 10.1200/JCO.2006.09.7634. View

Goncharova E, Goncharov D, Noonan D, Krymskaya V . TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol. 2004; 167(6):1171-82. PMC: 2172598. DOI: 10.1083/jcb.200405130. View

McCormack F . Lymphangioleiomyomatosis: a clinical update. Chest. 2008; 133(2):507-16. DOI: 10.1378/chest.07-0898. View

Volinia S, Dhand R, Vanhaesebroeck B, MacDougall L, Stein R, Zvelebil M . A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 1995; 14(14):3339-48. PMC: 394401. DOI: 10.1002/j.1460-2075.1995.tb07340.x. View

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

10.

Cloughesy T, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S . Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008; 5(1):e8. PMC: 2211560. DOI: 10.1371/journal.pmed.0050008. View

11.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

12.

Zhou X, Marsh D, Hampel H, Mulliken J, Gimm O, Eng C . Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet. 2000; 9(5):765-8. DOI: 10.1093/hmg/9.5.765. View

13.

Grahame Hardie D . AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2006; 47:185-210. DOI: 10.1146/annurev.pharmtox.47.120505.105304. View

14.

Jenne D, Reimann H, Nezu J, FRIEDEL W, Loff S, Jeschke R . Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998; 18(1):38-43. DOI: 10.1038/ng0198-38. View

15.

Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G . A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006; 95(9):1148-54. PMC: 2360568. DOI: 10.1038/sj.bjc.6603419. View

16.

Hsu Y, Chern J, Cai Y, Liu M, Choi K . Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature. 2007; 445(7129):785-8. DOI: 10.1038/nature05528. View

17.

Goncharova E, Goncharov D, Eszterhas A, Hunter D, Glassberg M, Yeung R . Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002; 277(34):30958-67. DOI: 10.1074/jbc.M202678200. View

18.

Li D, Sun H . TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997; 57(11):2124-9. View

19.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X . TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-68. DOI: 10.1016/j.cell.2006.06.055. View

20.

Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D . Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science. 1995; 269(5224):690-3. DOI: 10.1126/science.7624799. View